Cellectis

Update in progress

CLLS (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Cellectis S.A. is a clinical-stage biotechnological company focused on gene-editing with allogeneic CAR T-cell programs for immuno-oncology and other therapies. Its candidates include BALLI-01 (lasme-cel) for relapsed/refractory ALL, NatHaLi-01 (eti-cel) for relapsed/refractory B-NHL, ALPHA3 for LBCL, TRAVERSE for advanced/metastatic clear cell RCC, and a melanoma program. Founded in 1999, it is headquartered in Paris, France.

Company score

Sentiment: -0.16; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.15; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.19; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.08; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.12; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive